CVRx Launches Second-Generation Barostim Programmer

July 12, 2022 – CVRx, Inc. which developed an FDA-approved neuromodulation device to treat the symptoms of heart failure, announced the launch of the Barostim Programmer. A complete rollout of the new Barostim Programmer, which was approved by the FDA earlier this year, is planned across the United States through 2022.

CVRx stated that the second-generation programmer has a modernized design, operates on an upgraded cellular network that enables remote view access, and includes an improved user interface that simplifies implantable pulse generator programming. The new Barostim Programmer is compatible with all Barostim implantable systems.

According to the company, the implantable Barostim system delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA’s Breakthrough Device designation and is FDA approved for use in heart failure patients in the United States. In Europe, it has received CE Mark approval for heart failure and resistant hypertension.